European Archives - Page 1026 of 1167 - European Medical Journal

World Brain Day 2016 Devoted to the Ageing Brain

London, July 2016 – “It is becoming increasingly clear that neurological disorders, such as stroke and dementia but to name a few, are projected to rise…

The Role of IL-6 in Autoimmune Disease

Rheumatoid arthritis, or RA, is an incompletely understood disorder. The complex pathophysiology of RA is regulated in part by a network of different…

EMJ

Hip Surgery May Not Be Best Choice

EVIDENCE from a study carried out in the USA shows that arthroscopic hip surgery might not always be a suitable option for people with osteoarthritis…

EMJ

Adalimumab Drug Suppresses Inflammation in Rheumatoid Arthritis Patients

DISCOVERY of a new function in a widely used anti-inflammatory drug could offer new insight into the divergent efficacies of different medications which…

Review of the EuroPCR Congress 2016

Paris, France, played host to EuroPCR again this year; the city has a rich medical history from Paré to Pasteur and the innovations seen at this year’s…

EMJ Interventional Cardiology 4 [Suppl 13] 2016

Coronary artery disease (CAD) is the leading cause of mortality in patients ≥60 years old worldwide, and may result in stable angina, acute coronary…

Interventional Cardiology

EMJ Interventional Cardiology 4.1 2016

Welcome to the 2016 edition of EMJ Interventional Cardiology, an assortment of the latest news, research, and opinions from across the world from…

How Bioresorbable Vascular Can Be Beneficial for Patients in the Long-Term

Coronary artery disease (CAD) is the leading cause of mortality in patients ≥60 years old worldwide, and may result in stable angina, acute coronary…

Zika Experts: Varied Neurological Complications, Virus Still Detectable After Recovery

London, 14 July, 2016 – The International Congress on Neuromuscular Diseases (ICND) just drew to an end in Toronto. Among the many questions addressed…

U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis

Janssen Pharmaceuticals, Inc. announced that the U.S. FDA has granted Priority Review designation for the New Drug Application for a 500mg chewable tablet formulation of mebendazole